Document is current
Any future updates will be listed below
-
Authors
Levinsen, Anne Katrine Graudal https://orcid.org/0000-0003-0906-1873
Dalton, Susanne Oksbjerg
Jakobsen, Erik
Gögenur, Ismail
Borre, Michael
Zachariae, Robert
Christensen, Peter
Laurberg, Søren
de Nully Brown, Peter
Hölmich, Lisbet Rosenkrantz
Johansen, Christoffer
Kjær, Susanne K.
van de Poll-Franse, Lonneke
Kjaer, Trille Kristina
-
Funding
Funding for this research was provided by:
Danish Cancer Society ‘Knæk Cancer’ (R364-A21129)
Novo Nordisk Fonden (NNF18OC0052543)
Danish Cancer Society Scientific Committee (R269-A15811)
Helsefonden (20-B-0434)
- License Information
-
More Information
Article History
Received: 24 February 2025
Accepted: 3 June 2025
First Online: 14 June 2025
Declarations
:
: The SEQUEL study is approved by the National Board of Health Data (Region Zealand (REG-059–2021)). Ethical review and approval were waived for this study, as no human biological material was included in the project. The study was registered in the Danish Cancer Society Research Database (2019-DCRC-0066). We obtained informed consent from all participants in the study. Data were stored and protected following the guidelines of the Danish legislation regarding GDPR.
: The authors declare no competing interests.
: The study guarantor (AKGL) affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.
